ABBV Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 10.8% compared to AbbVie's net margin of 11.99%. AbbVie's return on equity of 58.92% beat Johnson & Johnson's return on equity of 20.88%.

AbbVie has a consensus price target of $202.54, signalling upside risk potential of 15.36%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 20.63%. Given that Johnson & Johnson has higher upside potential than AbbVie, analysts believe Johnson & Johnson is more attractive than AbbVie.

AbbVie has a beta of 0.576, which suggesting that the stock is 42.364% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

AbbVie has a quarterly dividend of $1.55 per share corresponding to a yield of 3.53%. Johnson & Johnson offers a yield of 3.36% to investors and pays a quarterly dividend of $1.24 per share. AbbVie pays 216.72% of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $14.5B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AbbVie's net income of $1.6B is lower than Johnson & Johnson's net income of $2.7B. Notably, AbbVie's price-to-earnings ratio is 60.97x while Johnson & Johnson's PE ratio is 23.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.61x versus 4.00x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 10.8% compared to AbbVie's net margin of 8.48%. AbbVie's return on equity of 58.92% beat Eli Lilly and's return on equity of 66.4%.

AbbVie has a consensus price target of $202.54, signalling upside risk potential of 15.36%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Eli Lilly and has higher upside potential than AbbVie, analysts believe Eli Lilly and is more attractive than AbbVie.

AbbVie has a beta of 0.576, which suggesting that the stock is 42.364% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

AbbVie has a quarterly dividend of $1.55 per share corresponding to a yield of 3.53%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. AbbVie pays 216.72% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $14.5B, which are larger than Eli Lilly and quarterly revenues of $11.4B. AbbVie's net income of $1.6B is higher than Eli Lilly and's net income of $970.3M. Notably, AbbVie's price-to-earnings ratio is 60.97x while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.61x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 10.8% compared to AbbVie's net margin of 18.95%. AbbVie's return on equity of 58.92% beat Merck &'s return on equity of 29.26%.

AbbVie has a consensus price target of $202.54, signalling upside risk potential of 15.36%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 31.29%. Given that Merck & has higher upside potential than AbbVie, analysts believe Merck & is more attractive than AbbVie.

AbbVie has a beta of 0.576, which suggesting that the stock is 42.364% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

AbbVie has a quarterly dividend of $1.55 per share corresponding to a yield of 3.53%. Merck & offers a yield of 3.18% to investors and pays a quarterly dividend of $0.81 per share. AbbVie pays 216.72% of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie quarterly revenues are $14.5B, which are smaller than Merck & quarterly revenues of $16.7B. AbbVie's net income of $1.6B is lower than Merck &'s net income of $3.2B. Notably, AbbVie's price-to-earnings ratio is 60.97x while Merck &'s PE ratio is 20.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.61x versus 3.95x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 10.8% compared to AbbVie's net margin of 25.23%. AbbVie's return on equity of 58.92% beat Pfizer's return on equity of 4.63%.

AbbVie has a consensus price target of $202.54, signalling upside risk potential of 15.36%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Pfizer has higher upside potential than AbbVie, analysts believe Pfizer is more attractive than AbbVie.

AbbVie has a beta of 0.576, which suggesting that the stock is 42.364% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

AbbVie has a quarterly dividend of $1.55 per share corresponding to a yield of 3.53%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. AbbVie pays 216.72% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie quarterly revenues are $14.5B, which are smaller than Pfizer quarterly revenues of $17.7B. AbbVie's net income of $1.6B is lower than Pfizer's net income of $4.5B. Notably, AbbVie's price-to-earnings ratio is 60.97x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.61x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.